Abstract: Methods of assessing cytolysis of cancer cells are provided, which include: providing a cell-substrate impedance monitoring device operably connected to an impedance analyzer, adding target cells characterized as cancer cells to a well of the device adding effector cells to the well to form a test well, where the effector cells are immune cells obtained or derived from a same patient as the target cells; monitoring cell-substrate impedance of the test well before and after adding the effector cells and optionally deriving an impedance-based parameter from the impedance; and determining effectiveness of effector cell killing of the target cells by comparing the impedance or impedance-based curves over time.

Abstract: Methods of assessing cytolysis of cancer cells are provided, which include: providing a cell-substrate impedance monitoring device operably connected to an impedance analyzer, adding target cells characterized as cancer cells to a well of the device adding effector cells to the well to form a test well, where the effector cells are immune cells obtained or derived from a same patient as the target cells; monitoring cell-substrate impedance of the test well before and after adding the effector cells and optionally deriving an impedance-based parameter from the impedance; and determining effectiveness of effector cell killing of the target cells by comparing the impedance or impedance-based curves over time.

Abstract: Methods of assessing cytolysis of cancer cells, including providing a cell-substrate impedance monitoring device operably connected to an impedance analyzer, wherein the device comprises a well for receiving cells and an electrode array at a base of the well; adding target cells characterized as cancer cells to the well; adding effector cells to the well to form a test well, wherein the effector cells are immune cells obtained or derived from a same patient as the target cells; monitoring cell-substrate impedance of the test well before and after adding the effector cells and optionally deriving an impedance-based parameter from the impedance; and determining effectiveness of effector cell killing of the target cells by comparing the impedance or impedance based parameter over time.

Abstract: Subscription-based systems and methods where a provider provides one or more customers, identified as subscribers or non-subscribers, with research products and services (e.g., for industries involved in genomic and proteomic research). Initially, the provider prepares collections of clones and provides customers with access to clone collections. Individual clones in a clone collection may comprise an ORF that may be flanked by recombination sites. Further, an ORF may contain a suppressible stop codon that may be suppressed to produce a fusion protein comprising the ORF and a tag sequence. Provider may provide additional related services and/or products. The products and services offered to the customers will vary depending on their designation as either subscribers or non-subscribers.

Abstract: Subscription-based systems and methods where a provider provides one or more customers, identified as subscribers or non-subscribers, with research products and services (e.g., for industries involved in genomic and proteomic research). Initially, the provider prepares collections of clones and provides customers with access to clone collections. Individual clones in a clone collection may comprise an ORF that may be flanked by recombination sites. Further, an ORF may contain a suppressible stop codon that may be suppressed to produce a fusion protein comprising the ORF and a tag sequence. Provider may provide additional related services and/or products. The products and services offered to the customers will vary depending on their designation as either subscribers or non-subscribers.